Silo Pharma, Inc.
SILO
Rank in Stocks
#32219
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm... Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Share Price
$1.63
Last synced: 2026-11-09
Market Cap
$1.84M
Change (1 day)
22.56%
Change (1 year)
-75.04%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Silo Pharma, Inc. (SILO)
Category
Healthcare
Operating Margin for Silo Pharma, Inc. (SILO)
Operating Margin as of November 2026 TTM: -8,250.46%
According to Silo Pharma, Inc.'s latest financial reports, its current operating margin (TTM) is -8,250.46%. At the end of 2025 the company had an operating margin of -5,936.95%.
Operating Margin history for Silo Pharma, Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -8,250.46% | 38.97% |
| 2025 | -5,936.95% | -9.03% |
| 2024 | -6,526.44% | 22.05% |
| 2023 | -5,347.41% | 6.28% |
| 2022 | -5,031.28% | 30.65% |
| 2021 | -3,850.95% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -2,293.38% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -55.51% | -194.40% |
| 2016 | 58.80% | -60.69% |
| 2015 | 149.58% | -35.62% |
| 2014 | 232.34% | -440.57% |
| 2013 | -68.22% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.98% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Silo Pharma, Inc.'s operating margin
What is Silo Pharma, Inc.'s operating margin?
Silo Pharma, Inc.'s operating margin is -8,250.46%, as of Nov 2026.
What was Silo Pharma, Inc.'s operating margin in 2025?
In 2025, Silo Pharma, Inc.'s operating margin was -5,936.95%, compared with -6,526.44% in 2024.
How has Silo Pharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Silo Pharma, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2024 (-6,526.44%).
How does Silo Pharma, Inc.'s operating margin compare with similar companies?
Silo Pharma, Inc.'s operating margin (-8,250.46%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.